Nama's AI scorecard currently rates Immunocore Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does IMCR report earnings?

Immunocore's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$0.17.

What is the IMCR price target?

The median analyst price target from 10 analysts is $57.50, with a range of $33.00 – $100.00.

Is IMCR Shariah compliant?

Nama's AAOIFI-style screen reads Immunocore as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Immunocore (IMCR)

Healthcare · Biotechnology · NASDAQ

Immunocore (IMCR) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.60B and a free-cash-flow yield of -1.0%. Over the most recent reported fiscal year, revenue grew 28.9% and free cash flow per share fell 171.6%. Nama's AI scorecard rates it Sell, 3.4 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.4/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -6.9% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-59.7%

How far the last close sits under the highest price of the past five years.

Market cap	$1.60B
Trailing P/E	—
Price / book	3.8
Price / sales	3.7
FCF yield	-1.0%
Dividend yield	—
Gross margin	98.8%
Operating margin	-7.1%
Net margin	-6.6%
Revenue growth (YoY)	+28.9%
Revenue growth (3-yr annual)	+31.9%
EPS growth (YoY)	—
FCF/share growth (YoY)	-171.6%
Beta	0.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

IMCR earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate -$0.17). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 6, 2026	-$0.28	-$0.14	-100.0%	—
Q2 2026	Aug 6, 2026	-$0.02	$0.02	-200.0%	$115.93M
Q1 2026	May 6, 2026	$0.25	-$0.26	+196.2%	$106.68M
Q4 2025	Feb 25, 2026	-$0.60	-$0.20	-200.0%	$104.48M

IMCR analyst price target

Median target $57.50 from 10 analysts, ranging $33.00 – $100.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live IMCR data on Nama Insights →

IMCR FAQ

Is IMCR a buy?: Nama's AI scorecard currently rates Immunocore Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does IMCR report earnings?: Immunocore's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$0.17.
What is the IMCR price target?: The median analyst price target from 10 analysts is $57.50, with a range of $33.00 – $100.00.
Is IMCR Shariah compliant?: Nama's AAOIFI-style screen reads Immunocore as Not Shariah Compliant. At least one of the three ratios or the industry test failed.